PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30254425-8	2018	Additionally, the expression of IL-1beta, IL-6, monocyte chemotactic protein-1, macrophage inflammatory protein-1alpha and TGF-beta were significantly decreased by tacrolimus.	Tacrolimus	164-174	interleukin 1 beta	Rattus norvegicus	32-40	
30713033-10	2019	RESULTS: In rats pre-treated with FK506, the levels of transaminases, TNF-alpha and IL-1beta were reduced significantly and also liver damage was dramatically mitigated compared to those without FK506 pre-treatment.	Tacrolimus	34-39	interleukin 1 beta	Rattus norvegicus	84-92	
15047987-4	2004	CsA (at concentrations of 10-50 microM), FK506 (at all used concentrations) and rapamycin (in dose-dependent manner) significantly attenuated IL-1beta release after 24 h exposure to ischemic conditions.	Tacrolimus	41-46	interleukin 1 beta	Rattus norvegicus	142-150	
17367747-5	2007	More specifically, Tacrolimus suppressed the expression of serum interleukin (IL-1beta), tumour necrosis factor (TNF-alpha), IL-6, airpouch exudate PGE(2) and leukocytosis usually observed after the induction of periodontitis.	Tacrolimus	19-29	interleukin 1 beta	Rattus norvegicus	78-86	
15390105-8	2005	In FK506-treated rats, a significant reduction of IL-1beta, IL-6, and TNF-alpha expression was observed 12 h after reperfusion.	Tacrolimus	3-8	interleukin 1 beta	Rattus norvegicus	50-58	
15390105-9	2005	FK506 neuroprotection was associated with a significant downregulation of IL-1beta expression in astrocytes and microglia in the injured side.	Tacrolimus	0-5	interleukin 1 beta	Rattus norvegicus	74-82	
15390105-10	2005	FK506 selectively decreased the levels of TNF-alpha, and IL-1beta mRNAs in astrocytes in vitro, with no effect on transforming growth factor-beta 1 (TGF-beta1) and IL-6 expression.	Tacrolimus	0-5	interleukin 1 beta	Rattus norvegicus	57-65	
27572744-9	2017	Moreover, the results in hypoxia-treated primary spinal cord microglia confirmed the effect of FK-506 on TNF-a, IL-1b, and IL-6 expression and NF-kappaB activation.	Tacrolimus	95-101	interleukin 1 beta	Rattus norvegicus	112-117	
22806180-5	2012	While both drugs efficiently reduced the expression of iNOS and the release of nitric oxide, only FK506 strongly inhibited the expression of Cox-2 and secretion of the mature form of IL-1beta.	Tacrolimus	98-103	interleukin 1 beta	Rattus norvegicus	183-191	
19815232-7	2011	Real-time RT-PCR and Western blotting showed that pretreatment with low-dose FK506 partially inhibited AIF-1 activation as well as its inducers (IFN-gamma and IL-1beta) in these three models.	Tacrolimus	77-82	interleukin 1 beta	Rattus norvegicus	159-167	
20402659-10	2010	Treatment with all three drugs (tacrolimus, somatostatin and glucocorticoids) resulted in a significant decrease of serum amylase, lung edema, and serum TNF-alpha and IL-1beta levels.	Tacrolimus	32-42	interleukin 1 beta	Rattus norvegicus	167-175	
17367747-6	2007	Tacrolimus treatment in periodontitis-induced rats conferred protection against the inflammation-induced tissue and bone loss associated with periodontitis, through a mechanism involving IL-1beta, TNF-alpha and IL-6.	Tacrolimus	0-10	interleukin 1 beta	Rattus norvegicus	187-195	
17612778-8	2007	This study shows that conversion from CsA to tacrolimus therapy leads to a reversal of the CsA-induced bone loss, which can probably be mediated by downregulation of IL-1beta, IL-6, and TNF-alpha production.	Tacrolimus	45-55	interleukin 1 beta	Rattus norvegicus	166-174	
10406194-8	1999	FK506 markedly inhibited the nitric oxide formation, inducible nitric oxide synthase protein synthesis and inducible nitric oxide synthase mRNA expression induced by interleukin 1beta, but cyclosporin A had no effects.	Tacrolimus	0-5	interleukin 1 beta	Rattus norvegicus	166-183	
12839866-20	2003	FK506 reduced IL-1beta and COX-2 mRNA expression and PGE(2) level in arthritic paws.	Tacrolimus	0-5	interleukin 1 beta	Rattus norvegicus	14-22	
11045663-9	2000	The optimal doses of CsA and tacrolimus had similar inhibitory effects on Th1 type cytokine IL-2 and interferon [INF]-gamma), inflammatory cytokine (IL-1beta and tumor necrosis factor [TNF]-alpha), and cytotoxic factor (granzyme B and perforin) mRNA expression.	Tacrolimus	29-39	interleukin 1 beta	Rattus norvegicus	149-157	
10510443-3	1999	Cyclosporin A and FK506 (at 1 microM) also significantly inhibited nitrite production induced by recombinant murine interferon-gamma (rIFNgamma) and recombinant murine interleukin-1beta (rIL-1beta) in J774 and VSMC, respectively.	Tacrolimus	18-23	interleukin 1 beta	Rattus norvegicus	187-196	
10406194-3	1999	Studies were performed to determine whether the immunosuppressants FK506 and cyclosporin A directly influence gene expression of inducible nitric oxide synthase by interleukin 1beta in hepatocytes.	Tacrolimus	67-72	interleukin 1 beta	Rattus norvegicus	164-181	
14528517-8	2003	FK506 caused a marked reduction of TNF-a and IL-1beta levels in paw tissue even in short-term (3-day) therapeutic treatment.	Tacrolimus	0-5	interleukin 1 beta	Rattus norvegicus	45-53	
14528517-12	2003	CONCLUSION: FK506 is more effective than MTX in reducing elevated levels of inflammatory cytokines TNF-a, IL-1beta, and IL-6 in established stages of AIA.	Tacrolimus	12-17	interleukin 1 beta	Rattus norvegicus	106-114	
7521274-5	1994	Both CsA and FK506 (at 1 mumol/L) significantly inhibited nitrite production induced by recombinant murine interleukin-1 beta (rIL-1 beta).	Tacrolimus	13-18	interleukin 1 beta	Rattus norvegicus	127-137	
8971291-12	1996	Water immersion stress increased gastric mucosal IL-1 beta and IL-2 contents 6 h after stress treatment, and these increases were prevented by FK506.	Tacrolimus	143-148	interleukin 1 beta	Rattus norvegicus	49-58